We are live on
!
Find out more
DMKJ
David M. Knott Jr Portfolio holdings
AUM
$189M
Turnover
22.11%
1-Year Est. Return
67.72%
This Fund
S&P 500
This Quarter
Est. Return
+18%
1 Year Est. Return
+67.72%
3 Year Est. Return
+169.37%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$189M
AUM Growth
+$21.1M
(+13%)
Cap. Flow
-$3.54M
Cap. Flow
% of AUM
-1.87%
Top 10 Holdings %
Top 10 Hldgs %
62.82%
Holding
95
New
10
Increased
16
Reduced
4
Closed
11
Avg Time Held
2.3
years
Top 10 Avg Time Held
1.4
years
Top 20 Avg Time Held
1.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Catalyst Bancorp
CLST
|
+$1.84M |
| 2 |
Spruce Biosciences
SPRB
|
+$1.12M |
| 3 |
Cullinan Oncology
CGEM
|
+$668K |
| 4 |
Insmed
INSM
|
+$515K |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
+$512K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Catalyst Pharmaceutical
CPRX
|
+$2.97M |
| 2 |
Arcellx
ACLX
|
+$2.23M |
| 3 |
Cytokinetics
CYTK
|
+$1.56M |
| 4 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$1.55M |
| 5 |
TG Therapeutics
TGTX
|
+$948K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 52.57% |
| 2 | Financials | 20.08% |
| 3 | Communication Services | 17.13% |
| 4 | Miscellaneous | 7.75% |
| 5 | Technology | 1.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Thermo Fisher Scientific
TMO
$255B
| $22.6K | 0.01% |
45
| – | – |
2022 Q2
16 quarters
|
|
77
Salesforce
CRM
$203B
| $12.1K | 0.01% |
77
| – | – |
2022 Q2
16 quarters
|
|
78
Starwood Property Trust
STWD
$4.75B
| $6.55K | ﹤0.01% |
400
| – | – |
2021 Q4
18 quarters
|
|
79
Kyndryl
KD
$2.76B
| $4.84K | ﹤0.01% |
428
| – | – |
2023 Q1
13 quarters
|
|
80
Occidental Petroleum Corp Warrants
OXY.WS
$36.4B
| $4.27K | ﹤0.01% |
+194
| New | +$6.75K |
2026 Q2
0 quarters
|
|
81
GE HealthCare
GEHC
$32B
| $3.2K | ﹤0.01% |
50
| – | – |
2023 Q4
10 quarters
|
|
82
Wabtec
WAB
$48.5B
| $1.62K | ﹤0.01% |
6
| – | – |
2021 Q4
18 quarters
|
|
|
83
DELISTED
Arcellx
ACLX
| – | – |
-19,433
| Closed | -$2.23M | – |
|
84
ADMA Biologics
ADMA
$2.42B
| – | – |
-60,200
| Closed | -$542K | – |
|
|
CNTA
85
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-39,000
| Closed | -$1.55M | – |
|
|
86
DELISTED
Catalyst Pharmaceutical
CPRX
| – | – |
-120,000
| Closed | -$2.97M | – |
|
|
87
Cytokinetics
CYTK
$8.93B
| – | – |
-23,644
| Closed | -$1.56M | – |
|
88
DuPont de Nemours
DD
$17.5B
| – | – |
-1,256
| Closed | -$173K | – |
|
89
Evolus
EOLS
$503M
| – | – |
-99,338
| Closed | -$408K | – |
|
90
Jasper Therapeutics
JSPR
$17.6M
| – | – |
-160,789
| Closed | -$141K | – |
|
91
Mereo BioPharma
MREO
$49.2M
| – | – |
-300,337
| Closed | -$99.1K | – |
|
92
LENZ Therapeutics
LENZ
$112M
| – | – |
-33,732
| Closed | -$309K | – |
|
Similar funds
SCA
FI
MFS
FRA
CAM
BAG
SHC
HC
David M. Knott Jr's Q2 2026 Portfolio in Review
As of Q2 2026, David M. Knott Jr held 95 positions worth $189M, up 13% from $168M the previous quarter. Its ten largest holdings account for 63% of the portfolio.
David M. Knott Jr's Q2 2026 filing shows 10 new, 16 increased, 4 reduced and 11 closed positions. Its largest new stake was Catalyst Bancorp: 114,000 shares worth $3.58M. The largest sale was Catalyst Pharmaceutical, an estimated $2.97M.
By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 54% a quarter earlier, followed by Financials and Communication Services.
- David M. Knott Jr's largest Q2 2026 buy was Catalyst Bancorp: 114,000 shares worth $3.58M.
- David M. Knott Jr added most to Cullinan Oncology in Q2 2026, an estimated $668K increase.
- David M. Knott Jr's biggest Q2 2026 reduction was TG Therapeutics, cutting an estimated $948K.
- David M. Knott Jr fully exited Catalyst Pharmaceutical in Q2 2026, selling an estimated $2.97M.
- David M. Knott Jr's ten largest holdings make up 63% of its $189M portfolio in Q2 2026.
- David M. Knott Jr opened 10 new positions and closed 11 in Q2 2026.
- David M. Knott Jr's portfolio value rose 13% quarter-over-quarter to $189M.
Based on David M. Knott Jr's 13F filing for Q2 2026, filed 12 Aug 2026.